Anti- SARS-CoV-2 Nucleocapsid IgM/ COVID-19, Humanized antibody (Positive Control)

Catalog# BDA1075

Lot # Check on the product label

Size 1 ml (100 µg/ml)

Isotype IgM

Clone # 2E4, monoclonal

Source Cultured in vitro, HEK293

Reactivity SARS-CoV-2

Product Form Liquid

Purification & Buffer

Protein A purified and supplied in 0.01 M PBS without preservative.

Purity >95% by HPLC & SDS-PAGE

Immunogen Recombinant SARS-CoV-2 nucleocapsid protein.

Recommend Application

Lateral flow (rapid test) (1:1000-100,000)

Chemiluminescence (1:10000-100,000)

This product is the prepared positive control for the assay.

Other applications have not been tested.

The optimal dilutions should be determined by end user.

Storage Instruction 

Aliquot and store at -20°C for long term (at least for one year).

Avoid repeated freeze and thaw cycles.

Background

The 2019 novel coronavirus, abbreviated as 2019-ncov, is a new strain of coronavirus discovered in the human body in 2019. The symptoms of the virus are fever, fatigue, dry cough, and progressive dyspnea. In severe cases, the symptoms are acute respiratory distress syndrome, septic shock, metabolic acidosis and coagulation dysfunction that can’t be corrected. The virus has been confirmed to exist the phenomenon of human-to-human transmission, the shortest incubation period of the virus is only 1 day, and the longest incubation period is 14 days. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.

Reference

1. World Health Organization: Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance.

2. "Pneumonia diagnosis and treatment program for novel coronavirus infection" of the National Health Commission of People’s Republic of China (Trial Version 3).